AstraZeneca will soon start a phase 3 trial of a subcutaneous version of its anti-CD19 T-cell engager.
ApexOnco Front Page
Recent articles
A son of glembatumumab vedotin has just started its phase 1 study.
The Japanese group licenses sapablursen from Ionis for $280m.
Safusidenib could eclipse the recently approved brain cancer drug, Nuvation claims.
The companies press on with vilastobart and IMPT-314... up to a point.
Recent first-in-human trials include Pheast and Auron, plus new targets from Immunocore and Cero.
The Pfizer-partnered vepdegestrant shows a benefit in ESR1 mutants, but not in all-comers.
The company has caught up with Syndax and overtaken Kura in the first-line menin inhibitor race.
